Bicalutamide (Casodex™) versus Placebo in patients with Early Prostate Cancer
Study identifier:D6876C00023
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Randomized Double-Blind Comparative Trial of Bicalutamide (Casodex™) Versus Placebo in patients with Early Prostate Cancer.
Medical condition
Non-metastatic prostate cancer
Phase
Phase 3
Healthy volunteers
No
Study drug
Bicalutamide, Placebo
Sex
Male
Actual Enrollment
3618
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Aug 1995
Primary Completion Date: 01 Jul 2008
Study Completion Date: 01 Aug 2008
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: Bicalutamide 150mg daily Other Name: Casodex™ |
| Placebo Comparator: 2 | Drug: Placebo once daily |
Contacts
Investigators
Principal Investigator
William See
Medical College of Wisconsin
